MAPT and Alzheimer disease: Recently, HDAC inhibitors have been established in patients with AD as potential targets due to their wide scope of effects, ranging from decreased deposition of Amyloid β-peptides, an immune response triggered by microglia, reduced β-secretase cleavage, regulated levels of SIRT1, BDNF, ABCA7, REST, LTP deficits and decreased phosphorylation and acetylation of Tau (Wang et al., 2019a; Rusek et al., 2019).